C-o- Group In R Patents (Class 514/622)
  • Publication number: 20120232105
    Abstract: A pharmaceutical composition for inhibiting osteoclast growth is disclosed in the present invention. The pharmaceutical composition includes a compound represented by a formula (I), and a pharmaceutically acceptable salt and carrier: wherein R1, R2, R3, R4 can be one selected from a group consisting of hydrogen, halogen, C1?C10 alkyl group, C2?C10 alkynyl group, amino group, haloalkyl group and sulfonamide group.
    Type: Application
    Filed: July 11, 2011
    Publication date: September 13, 2012
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Deh-Ming CHANG, Hsu-Shan Huang
  • Publication number: 20120232155
    Abstract: The invention relates to a novel hydroxyphenyl compound, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound.
    Type: Application
    Filed: November 11, 2009
    Publication date: September 13, 2012
    Inventors: Vincent Gerusz, Fabien Faivre, Mayalen Oxoby, Alexis Denis, Yannick Bonvin
  • Publication number: 20120219611
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: ALLERGAN, INC.
    Inventor: PATRICK M. HUGHES
  • Publication number: 20120214858
    Abstract: Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.
    Type: Application
    Filed: August 16, 2010
    Publication date: August 23, 2012
    Applicant: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald, Thomas P. Mathews, Andrew Kennedy, Yugesh Kharel
  • Publication number: 20120214782
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 17, 2011
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerald Juergen ROTH, Martin FLECK, Heike NEUBAUER, Bernd NOSSE
  • Publication number: 20120202886
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
    Type: Application
    Filed: April 6, 2012
    Publication date: August 9, 2012
    Applicant: ALLERGAN, INC.
    Inventors: David F. WOODWARD, Amanda M. VANDENBURGH
  • Patent number: 8227643
    Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: July 24, 2012
    Assignee: ProteoTech, Inc.
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
  • Publication number: 20120184553
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 27, 2010
    Publication date: July 19, 2012
    Inventors: Paula Louise Nichols, Andrew John Eatherton, Paul Bamborough, Karamjit Singh Jandu, Oliver James Philps, Daniele Andreotti
  • Publication number: 20120178747
    Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.
    Type: Application
    Filed: November 14, 2006
    Publication date: July 12, 2012
    Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
  • Publication number: 20120178749
    Abstract: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such inhibitors are contemplated by the present invention.
    Type: Application
    Filed: February 21, 2012
    Publication date: July 12, 2012
    Inventors: Michael Roth, Beatriz Fontoura, Shuguang Wei, Neal Satterly
  • Patent number: 8216971
    Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: July 10, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Koen van Den Eynde, Wolfgang Thielert, Heike Hungenberg
  • Patent number: 8211882
    Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: July 3, 2012
    Inventors: Richard Delarey Wood, William J Welsh, Sean Ekins, Ni Ai
  • Publication number: 20120165339
    Abstract: A cyclopropane derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof has orexin receptor inhibitory action, and thus, is extremely useful as an agent for preventing or treating sleep disorder or dyssomnia caused by orexin, including insomnia as a typical example: wherein A1, A2 and A3 each independently represent an aryl group, a heterocyclyl group or the like, R1, R2 and R3 each independently represent a hydrogen atom, a C1-6 alkyl group or the like, X represents an oxygen atom or the like, and L represents a bond or the like.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 28, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Terauchi, Ayumi Takemura, Yuji Kazuta, Fumihiro Ozaki, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann
  • Publication number: 20120165293
    Abstract: The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.
    Type: Application
    Filed: July 13, 2010
    Publication date: June 28, 2012
    Inventors: George Petros Yiannikouros, Panos Kalaritis, Chaminda Priyapushpa Gamage, Stephenie Bosse Abernathy
  • Patent number: 8206695
    Abstract: Effective enhancement of eyelash length and density can be obtained by topical applications of an active agent selected from a class of compounds consisting of synthetic prostaglandin agonists, polymers thereof and mixtures thereof preferably having the chemical formula of C24H35NO5, such as 7-[3.5-dihydroxy-2-(3-hydroxy-4phenoxy-but-1-enyl)-cyclopentyl]-hept-5-enoic acid ethylamide. Such active agents having a molecular weight of 417.54 can be employed in concentrations from 0.00075% to 0.03% by weight in mixtures with inactive ingredients, such as gels, oils, etc. Results are obtained by daily topical applications of active agent in such liquid mixtures (tinctures) at the roots of the lashes and/or lash follicles.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: June 26, 2012
    Assignee: La Canada Ventures, Inc.
    Inventor: Suan Lin
  • Patent number: 8198332
    Abstract: The application discloses compounds of Formula I: wherein Q1, Q2, R1, R2, R3, and n are defined as described herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: June 12, 2012
    Assignee: Roche Palo Alto LLC
    Inventor: Todd Richard Elworthy
  • Publication number: 20120142783
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: February 10, 2012
    Publication date: June 7, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20120142771
    Abstract: The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R4 and R5 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R6 and R7 are independently selected from the group consisting of hydrogen atom, fluorine atom, methyl, ethyl, hydroxy group, and others; and R8 and R9 are independently selected from the group consisting of hydrogen atom, C1-6 alkyl, and others, which is useful as an agent for treating or preventing various types of epilepsy including partial seizures and/or generalized seizures.
    Type: Application
    Filed: February 7, 2012
    Publication date: June 7, 2012
    Applicant: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Seiji IWAMA, Tomoyuki Tanaka, Nana Yajima
  • Publication number: 20120142782
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: February 10, 2012
    Publication date: June 7, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20120122918
    Abstract: Compounds of formula (1) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)—; R1 is hydrogen and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; and R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)-Q.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 17, 2012
    Applicant: BIOTA SCIENTIFIC MANAGEMENT PTY LTD
    Inventors: David Ryall BROWN, Ian COLLINS, Lloyd George CZAPLEWSKI, David John HAYDON
  • Publication number: 20120122976
    Abstract: The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 17, 2012
    Applicant: URSAPHARM ARZNEIMITTEL GMBH
    Inventor: Frank Holzer
  • Publication number: 20120122934
    Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
    Type: Application
    Filed: May 18, 2011
    Publication date: May 17, 2012
    Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
  • Publication number: 20120122989
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: ALLERGAN, INC.
    Inventors: David F. Woodward, Amanda M. Vandenburgh
  • Publication number: 20120108666
    Abstract: The invention relates to compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Inventor: Eliahu Kaplan
  • Publication number: 20120108592
    Abstract: A new class of salicylanilides is described. These compounds show strong activity against hepatitis viruses.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 3, 2012
    Inventors: J. Edward Semple, Jean-Francois Rossignol
  • Publication number: 20120101087
    Abstract: The present invention relates to, in part, novel bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising the same.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 26, 2012
    Inventors: Randall S. Alberte, Robert D. Smith
  • Publication number: 20120093742
    Abstract: A method of modulating the flavour of an orally-receivable product, such as a foodstuff, beverage, dentifrice or medicine, comprising the addition thereto of a flavour-modulating proportion of at least one compound of the formula I in which X is selected from CHOH, C?O, CH2—CO and CH?C(OH), Y is selected from C1-C7 linear and branched alkyl and CH2CH2OH, Z is selected from CH3 and a moiety of the formula II in which the wavy bond represents bond linking Z to X and R1 and R2 are selected from the possibilities (i) both hydrogen; (ii) independently OH and OCH3; and (iii) R1 and R2 together with their bonds to the phenyl ring form a ring of the formula —O—CH2—O—; such that, when Z is CH3, X is C?O and Y is CH2CH2OH.
    Type: Application
    Filed: June 24, 2010
    Publication date: April 19, 2012
    Applicant: Givaudan S.A.
    Inventors: Abdelmajid Kaouas, Harry Renes, Alexander P. Tondeur, Cornelis Winkel
  • Patent number: 8158682
    Abstract: This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the pharmaceutical composition to dwell for a predetermined period of time, and aspirating the wound or incision to remove the pharmaceutical composition. The invention also provides a method for attenuating pain in proximity to a joint comprising intra-articularly injecting a pharmaceutical composition comprising a capsaicinoid into the joint, allowing the pharmaceutical composition to dwell for predetermined period of time, and aspirating the joint to remove the pharmaceutical composition. In certain embodiments of the invention, the capsaicinoid is capsaicin.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: April 17, 2012
    Assignee: Vallinex, Inc.
    Inventors: Lakshmi Sangameswaran, Susan Kramer
  • Publication number: 20120077845
    Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 29, 2012
    Inventors: James T. DALTON, Mitchell S. STEINER, Ronald A. MORTON
  • Publication number: 20120065247
    Abstract: Provided herein are compounds and methods for use in preventing or treating a viral infection mediated by a virus comprising an IRES-containing RNA molecule or cancer related to an increase or decrease in IRES-mediated translation of an RNA molecule. Also provided are methods of inhibiting or promoting IRES-mediated translation. Also provided are methods of screening for an agent that inhibits IRES-mediated translation.
    Type: Application
    Filed: March 26, 2010
    Publication date: March 15, 2012
    Applicants: DiscoveryBiomed, Inc., The UAB Research Foundation
    Inventors: Sunnie R. Thompson, Erik Mills Schwiebert, John H. Streiff
  • Publication number: 20120059064
    Abstract: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.
    Type: Application
    Filed: June 28, 2011
    Publication date: March 8, 2012
    Applicant: MitoTek, LLC
    Inventor: Paul Q. Anziano
  • Publication number: 20120046293
    Abstract: The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: October 10, 2011
    Publication date: February 23, 2012
    Applicant: Merck Frosst Canada Ltd.
    Inventors: CHRISTOPHER I. BAYLY, Austin C. Chen, Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Dwight MacDonald, Daniel McKay, David A. Powell, Erich L. Grimm
  • Patent number: 8114898
    Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: February 14, 2012
    Assignee: Allergan, Inc.
    Inventors: Stuart D. Shanler, Andrew Ondo
  • Publication number: 20120022039
    Abstract: The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according to the invention or derivative thereof, and to the use of the substituted indanes according to the invention and to derivatives thereof as MCH antagonists.
    Type: Application
    Filed: February 12, 2010
    Publication date: January 26, 2012
    Applicant: SANOFI
    Inventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Klaus Wirth
  • Publication number: 20120015978
    Abstract: This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.
    Type: Application
    Filed: June 27, 2011
    Publication date: January 19, 2012
    Applicant: ALLERGAN, INC.
    Inventor: David W. Old
  • Patent number: 8097759
    Abstract: A medicament having inhibitory activity against NF-?B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 17, 2012
    Assignee: Institute of Medicinal Molecular Design, Inc.
    Inventors: Susumu Muto, Tatsuo Nagano, Tomomi Sotome, Akiko Itai
  • Publication number: 20120010178
    Abstract: Methods, compounds and compositions for promoting motor neuron survival and the treatment of a neurodegenerative disorders such as Spinal Muscular Atrophy (SMA) are described herein.
    Type: Application
    Filed: October 21, 2009
    Publication date: January 12, 2012
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Lee Rubin, Amy Sinor, Nina Ruslanovna Makhortova, Yin Miranda Yang, Monica Hayhurst Bennett
  • Publication number: 20110319487
    Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.
    Type: Application
    Filed: June 28, 2011
    Publication date: December 29, 2011
    Applicant: Laboratoires THEA
    Inventor: Fabrice Mercier
  • Publication number: 20110311623
    Abstract: The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient having lower hardness than the coated active substance and another excipient having higher hardness and larger particle size than the active substance are used as means for protecting the coating layer from being destroyed.
    Type: Application
    Filed: March 12, 2008
    Publication date: December 22, 2011
    Inventors: Mikyoung Hahn, Jin-Woo Choi, Dae-Hyeon Kim
  • Publication number: 20110313038
    Abstract: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ?2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 22, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
  • Patent number: 8080541
    Abstract: The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: December 20, 2011
    Assignee: Hoffman-La Roche Inc.
    Inventors: Sabine Kolczewski, Emmanuel Pinard
  • Publication number: 20110301179
    Abstract: A compound (particularly useful for inhibiting cancer) according to formula I: or a pharmaceutically acceptable salt thereof, wherein: x is 0 or 1; R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl; R7 is H, alkyl, alkyl amino, aminoacyl, hydroxyacyl, heteroaryl, heterocycloalkyl, alkyl heteroaryl or alkyl heterocycloalkyl; R8 is H or alkyl; A is O or N; and Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, provided that if R7 is H then Ar is aryl substituted with alkyl amino.
    Type: Application
    Filed: October 21, 2009
    Publication date: December 8, 2011
    Inventors: Xiangshu Xiao, Bingbing Li
  • Patent number: 8071575
    Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: December 6, 2011
    Assignee: University of Louisville Research Foundation
    Inventors: William M. Pierce, Jr., K. Grant Taylor, Leonard C. Waite
  • Publication number: 20110294880
    Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.
    Type: Application
    Filed: August 10, 2011
    Publication date: December 1, 2011
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Yusuke SAKAI, Akira Ohtori
  • Publication number: 20110294893
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 1, 2011
    Applicant: ALLERGAN, INC.
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • Publication number: 20110293549
    Abstract: Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by: wherein A and B are individually selected from a hydrogen, a hydroxyl group and a halogen, with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen and when one of A and B is a halogen, the other of A and B is a halogen or a hydrogen; wherein Z is, for example, an aryl moiety; and wherein X1 and X2 are, for example, individually selected from a hydrogen and an alkyl moiety, wherein R1 and R2 are individually selected from an oxo, a hydroxyl or an ester group; wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt.
    Type: Application
    Filed: February 2, 2010
    Publication date: December 1, 2011
    Applicant: ATHENA COSMETICS, INC.
    Inventor: MICHAEL C. BRINKENHOFF
  • Publication number: 20110288179
    Abstract: The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.
    Type: Application
    Filed: May 23, 2011
    Publication date: November 24, 2011
    Inventors: Arie GUTMAN, Igor Rukhman, Boris Tishin, Lev Yudovich, Alexander Vilensky, Boris Pertsikov, Gennady Nisnevich
  • Publication number: 20110275603
    Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Applicants: Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
    Inventors: Meyyappan MUTHUPPALANIAPPAN, Prashant K. BHAVAR, Srikant VISWANADHA, Swaroop Kumar V.S. VAKKALANKA, Gayatri S. MERIKAPUDI
  • Publication number: 20110275577
    Abstract: The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.
    Type: Application
    Filed: January 10, 2011
    Publication date: November 10, 2011
    Applicant: Moleculin, LLC
    Inventors: Anna Priebe, Waldemar Priebe
  • Publication number: 20110269834
    Abstract: Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).
    Type: Application
    Filed: August 21, 2009
    Publication date: November 3, 2011
    Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, PURDUE RESEARCH FOUNDATION
    Inventors: Arun K. Ghosh, Jun Takayama, Andrew David Mesecar, Michael E. Johnson, Kiira M. Ratia, Rima Chaudhuri, Debbie C. Mulhearn